Indian Journal of Dermatology
CASE REPORT
Year
: 2020  |  Volume : 65  |  Issue : 3  |  Page : 214--216

Nivolumab-induced bullous pemphigoid managed without drug withdrawal


Mónica Munera-Campos, Adrià Plana-Pla, Noelia Rivera, Aram Boada, Carlos Ferrándiz 
 Department of Dermatology, Germans Trias I Pujol University Hospital, Universitat Autònoma De Barcelona, Badalona, Spain

Correspondence Address:
Mónica Munera-Campos
Department of Dermatology, Germans Trias I Pujol University Hospital, Universitat Autonoma De Barcelona, Carretera De Canyet, S/N, 08916 Badalona, Barcelona
Spain

The widespread use of anti-programmed cell death receptor-1 (PD-1) agents has shed light to unusual immune-related adverse effects, especially affecting the skin. We report a case of bullous pemphigoid secondary to nivolumab therapy for metastatic renal carcinoma with a previously unreported complete response to clobetasol ointment alone. The autoimmune blistering disease was successfully treated without oral corticosteroids, and the anti-PD-1 agent could be maintained without recurrence of the skin lesions. Topical therapy remains a good option in selected, mild-to-moderate cases of induced bullous pemphigoid.


How to cite this article:
Munera-Campos M, Plana-Pla A, Rivera N, Boada A, Ferrándiz C. Nivolumab-induced bullous pemphigoid managed without drug withdrawal.Indian J Dermatol 2020;65:214-216


How to cite this URL:
Munera-Campos M, Plana-Pla A, Rivera N, Boada A, Ferrándiz C. Nivolumab-induced bullous pemphigoid managed without drug withdrawal. Indian J Dermatol [serial online] 2020 [cited 2021 Jan 16 ];65:214-216
Available from: https://www.e-ijd.org/article.asp?issn=0019-5154;year=2020;volume=65;issue=3;spage=214;epage=216;aulast=Munera-Campos;type=0